Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis

被引:5
作者
Chacko, Archana [1 ]
Wen, Sophie C. H. [1 ]
Hartel, Gunter [2 ]
Kapur, Nitin [1 ]
Wainwright, Claire E. [1 ,3 ]
Clark, Julia E. [1 ,3 ]
机构
[1] Lady Cilento Childrens Hosp, Brisbane, Qld 4101, Australia
[2] Queensland Inst Med Res, Brisbane, Qld, Australia
[3] Univ Queensland, Brisbane, Qld, Australia
关键词
pediatric cystic fibrosis; Mycobacterium abscessus treatment; Mycobacterium abscessus pulmonary disease; NONTUBERCULOUS MYCOBACTERIA; INFECTIONS;
D O I
10.1097/INF.0000000000002274
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Mycobacterium abscessus complex pulmonary disease (M. abscessus PD) in cystic fibrosis (CF) is challenging to treat. Current guideline therapeutic regimens involving an intensive phase of intravenous (IV) antibiotics followed by a consolidation phase of inhaled and oral antibiotics are not evidence-based. The objectives of this study were to characterize the clinical outcomes and clearance of Mycobacterium abscessus complex (M. abscessus) from respiratory cultures in children with CF M. abscessus PD. Methods: This retrospective longitudinal cohort analysis evaluated the first course of treatment for M. abscessus PD in 33 children in Queensland, Australia between 2001 and 2015. Spirometry and nutritional outcomes 2 years pretreatment and 1 year posttreatment were compared with clearance or relapse/persistence of Mycobacterium abscessus complex from respiratory cultures. Results: Nine of 18 children who completed therapy, cleared infection. Three of 7 children who completed only intensive therapy cleared sputum compared with 0/8 children who did not. The trajectory of the percent predicted forced expiratory volume in 1 s and age standardized body mass index significantly improved posttreatment in those that cleared sputum (P < 0.0001). Conclusions: These results suggest that current treatment recommendations for M. abscessus PD are associated with some success in clearing infection in children with CF and improvement in lung function and body mass index. Clinical trials are required to determine the best treatment approaches.
引用
收藏
页码:660 / 666
页数:7
相关论文
共 19 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection A Prospective Cohort Study [J].
Czaja, Christopher A. ;
Levin, Adrah R. ;
Cox, Christian W. ;
Vargas, Daniel ;
Daley, Charles L. ;
Cott, Gary R. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (01) :40-48
[3]   Nontuberculous mycobacterial infection in young children with cystic fibrosis [J].
Esther, CR ;
Henry, MM ;
Molina, PL ;
Leigh, MW .
PEDIATRIC PULMONOLOGY, 2005, 40 (01) :39-44
[4]   US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary [J].
Floto, R. Andres ;
Olivier, Kenneth N. ;
Saiman, Lisa ;
Daley, Charles L. ;
Herrmann, Jean-Louis ;
Nick, Jerry A. ;
Noone, Peadar G. ;
Bilton, Diana ;
Corris, Paul ;
Gibson, Ronald L. ;
Hempstead, Sarah E. ;
Koetz, Karsten ;
Sabadosa, Kathryn A. ;
Sermet-Gaudelus, Isabelle ;
Smyth, Alan R. ;
van Ingen, Jakko ;
Wallace, Richard J. ;
Winthrop, Kevin L. ;
Marshall, Bruce C. ;
Haworth, Charles S. .
THORAX, 2016, 71 (01) :88-90
[5]   Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis [J].
Forslöw, U ;
Geborek, A ;
Hjelte, L ;
Petrini, B ;
Heurlin, N .
ACTA PAEDIATRICA, 2003, 92 (08) :910-915
[6]   An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [J].
Griffith, David E. ;
Aksamit, Timothy ;
Brown-Elliott, Barbara A. ;
Catanzaro, Antonino ;
Daley, Charles ;
Gordin, Fred ;
Holland, Steven M. ;
Horsburgh, Robert ;
Huitt, Gwen ;
Iademarco, Michael F. ;
Iseman, Michael ;
Olivier, Kenneth ;
Ruoss, Stephen ;
von Reyn, C. Fordham ;
Wallace, Richard J., Jr. ;
Winthrop, Kevin .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (04) :367-416
[7]   British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) [J].
Haworth, Charles S. ;
Banks, John ;
Capstick, Toby ;
Fisher, Andrew J. ;
Gorsuch, Thomas ;
Laurenson, Ian F. ;
Leitch, Andrew ;
Loebinger, Michael R. ;
Milburn, Heather J. ;
Nightingale, Mark ;
Ormerod, Peter ;
Shingadia, Delane ;
Smith, David ;
Whitehead, Nuala ;
Wilson, Robert ;
Floto, R. Andres .
THORAX, 2017, 72 :ii1-ii64
[8]   Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease [J].
Koh, Won-Jung ;
Jeong, Byeong-Ho ;
Kim, Su-Young ;
Jeon, Kyeongman ;
Park, Kyoung Un ;
Jhun, Byung Woo ;
Lee, Hyun ;
Park, Hye Yun ;
Kim, Dae Hun ;
Huh, Hee Jae ;
Ki, Chang-Seok ;
Lee, Nam Yong ;
Kim, Hong Kwan ;
Choi, Yong Soo ;
Kim, Jhingook ;
Lee, Seung-Heon ;
Kim, Chang Ki ;
Shin, Sung Jae ;
Daley, Charles L. ;
Kim, Hojoong ;
Kwon, O. Jung .
CLINICAL INFECTIOUS DISEASES, 2017, 64 (03) :309-316
[9]  
Lee MR, 2015, EMERG INFECT DIS, V21, P1638, DOI [10.3201/eid2109.141634, 10.3201/2109.141634]
[10]  
Martiniano Stacey L, 2014, Ann Am Thorac Soc, V11, P36, DOI 10.1513/AnnalsATS.201309-310OC